Open AccessProlonged overall survival in metastatic gastric cancer treated with ipilimumab and lapatinib
Author(s) -
Yanfang Ju,
Shengjie Sun,
Shunchang Jiao
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_508_17
Subject(s) - medicine , lapatinib , ipilimumab , cancer , oncology , trastuzumab , carcinoembryonic antigen , immunotherapy , lymph node , breast cancer
Gastric cancer is one of the most important common tumors in the world. It remains the second leading cause of cancer-related death worldwide. The prognosis of patients with unresectable or metastatic gastric cancer remains poor. New targeted drugs were evaluated in clinic, such as lapatinib. The potential for making beneficial progress is to investigate innovative therapeutic strategies, such as immunotherapy.